HRMY
Harmony Biosciences Holdings, Inc.
October 12, 2026 · intraday
- Rarity
- 1.65
- Peak move
- −7.62%
- Float cap
- $2.0B
Harmony Biosciences Holdings, Inc. is a neuroscience company focused on rare neurological diseases. It commercializes WAKIX (pitolisant), an FDA-approved oral treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy, and is developing therapies for idiopathic hypersomnia, Prader-Willi syndrome, rare epilepsies, and other central nervous system disorders.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
4 events · 0 from SEC or newswire · 0 timed with the move- Key event
ceo_cfo_departureHarmony Biosciences announced a planned CEO transition: President and CEO Jeffrey M. Dayno, M.D. will retire and step down from the board on December 31, 2026, after nine years, serving as a non-executive advisor through 2027, and Peter Anastasiou, Sr. EVP and COO and a former board member who previously led Capsida Biotherapeutics and was President of North America at Lundbeck, was appointed President, CEO and board member effective January 1, 2027.
- Key event
analyst_ratingNeedham & Company reiterated a Buy rating on Harmony Biosciences on October 12, 2026, with analyst Ami Fadia noting management stressed the CEO transition comes from a position of strength.
- Key event
guidance_changeHarmony Biosciences reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and said it remains on track to report MAD study data for BP-205 in Q4 2026.
notable_investor_commentMizuho analyst Graig Suvannavejh said Harmony Biosciences' promotion of COO Peter Anastasiou to CEO came as no major surprise and kept an Outperform rating on the shares.